

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2022

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 16: Therapie der juvenilen idiopathischen Arthritis. *Von Dr. Ivan Foeldvari*

1. Rigante D, Bosco A, Esposito S. The Etiology of Juvenile Idiopathic Arthritis. *Clin Rev Allergy Immunol.* 2015;49(2):253-61.
2. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. *Joint Bone Spine.* 2014;81(2):112-7.
3. Ravelli A, Martini A. Juvenile idiopathic arthritis. *Lancet.* 2007;369(9563):767-78.
4. Costello R, McDonagh J, Hyrich K, Humphreys J. Incidence and prevalence of Juvenile Idiopathic Arthritis in the United Kingdom 2000-2018: results from the Clinical Practice Research Datalink. *Rheumatology (Oxford).* 2021.
5. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol.* 2004;31(2):390-2.
6. Colver T. The prognosis in rheumatoid arthritis in childhood. *Arch Dis Child.* 1937;12(70):253-60.
7. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken).* 2013;65(5):745-52.
8. Haasnoot AJW, Sint Jago NFM, Tekstra J, de Boer JH. Impact of Uveitis on Quality of Life in Adult Patients With Juvenile Idiopathic Arthritis. *Arthritis Care Res (Hoboken).* 2017;69(12):1895-902.
9. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeff AS et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. *Arthritis Rheum.* 2012;64(6):2012-21.
10. Baidam E. A commentary on TREAT: the trial of early aggressive drug therapy in juvenile idiopathic arthritis. *BMC Med.* 2012;10:59.
11. Cabrera N, Lega JC, Kassai B, Wouters C, Kondi A, Cannizzaro E et al. Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohort database. *Joint Bone Spine.* 2019;86(3):343-50.
12. Aeschlimann FA, Chong SL, Lyons TW, Beinvoogl BC, Goetz-Mogollon LM, Tan S et al. Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses. *J Pediatr.* 2019;204:162-71 e3.
13. Dumaine C, Bekkar S, Belot A, Cabrera N, Malik S, von Scheven A et al. Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohort. *Joint Bone Spine.* 2020;87(1):49-55.
14. Gronlund MM, Remes-Pakarinen T, Kroger L, Markula-Patjas K, Backstrom M, Putto-Laurila A et al. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis. *Rheumatology (Oxford).* 2020;59(4):732-41.
15. Ong MS, Ringold S, Kimura Y, Schanberg LE, Tomlinson GA, Natter MD et al. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. *Arthritis Rheumatol.* 2021;73(10):1910-20.
16. Kimura Y, Schanberg LE, Tomlinson GA, Riordan ME, Denny AC, Del Gaizo V et al. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. *Arthritis Rheumatol.* 2021;73(10):1898-909.
17. Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P et al. Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. *Arthritis Care Res (Hoboken).* 2019;71(4):471-81.

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2022

Seite 2

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

18. Chhabra A, Oen K, Huber AM, Shiff NJ, Boire G, Benseler SM et al. Real-World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort. *Arthritis Care Res (Hoboken)*. 2020;72(7):897-906.
19. Baltruschat K, Deuter C, Foeldvari I, Ganser G et al. S2k-Leitlinie „Therapie der Juvenilen Idiopathischen Arthritis“. AWMF online. 2019.
20. Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. *Ann Rheum Dis*. 2019;78(1):51-9.
21. Hissink Muller PCE, van Braak WG, Schreurs D, Nusman CM, Bergstra SA, Hemke R et al. No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis. *Pediatr Rheumatol Online J*. 2019;17(1):62.
22. Shoop-Worrall SJW, Verstappen SMM, McDonagh JE, Baildam E, Chieng A, Davidson J et al. Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition. *Arthritis Rheumatol*. 2018;70(9):1519-29.
23. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, Childhood Arthritis Rheumatology Research A et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)*. 2011;63(7):929-36.
24. Foeldvari I, Klotsche J, Simonini G, Edelsten C, Angeles-Han ST, Bangsgaard R et al. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC). *Pediatr Rheumatol Online J*. 2019;17(1):66.
25. Klein-Wieringa IR, Brinkman DMC, Ten Cate R, Hissink Muller PCE. Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible? *Curr Opin Rheumatol*. 2020;32(5):403-13.
26. Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. *Ann Rheum Dis*. 2018;77(6):819-28.
27. Schoemaker CG, Swart JF, Wulffraat NM. Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals? *Pediatr Rheumatol Online J*. 2020;18(1):34.
28. Horneff G, Klein A, Ganser G, Sailer-Hock M, Gunther A, Foeldvari I et al. Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. *Pediatr Rheumatol Online J*. 2017;15(1):78.
29. Raab A, Kallinich T, Huscher D, Foeldvari I, Weller-Heinemann F, Dressler F et al. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry. *Pediatr Rheumatol Online J*. 2021;19(1):41.
30. Hospach T, Horneff G, Poddubnyy D. Spondyloarthritis in childhood and adulthood. *Z Rheumatol*. 2022.
31. Baer J, Klotsche J, Foeldvari I. Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index. *Clin Exp Rheumatol*. 2021.
32. Ho ACH, Wong SN, Leung LCK, Chan WKY, Chong PCY, Tse NKC et al. Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement. *Hong Kong Med J*. 2020;26(1):56-65.
33. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? *Arthritis Rheumatol*. 2014;66(6):1405-13.

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2022

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

34. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. *Ann Rheum Dis.* 2015;74(10):1854-60.
35. Halyabar O, Mehta J, Ringold S, Rumsey DG, Horton DB. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature. *Paediatr Drugs.* 2019;21(6):469-92.
36. Renton WD, Munro J, Avery J, Whittle S, Arno A, Buchbinder R. Dose reduction and discontinuation of disease-modifying antirheumatic drugs (DMARDs) for juvenile idiopathic arthritis (Protocol). *Cochrane Database of Systematic Reviews.* 2022(1).
37. Horton DB, Onel KB, Beukelman T, Ringold S. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. *J Rheumatol.* 2017;44(3):352-60.
38. Shenoi S, Nanda K, Schulert GS, Bohnsack JF, Cooper AM, Edghill B et al. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey. *Pediatr Rheumatol Online J.* 2019;17(1):4.

Angaben zu möglichen Interessenkonflikten: vorhanden

Advisory Board: Novartis, Pfizer, Hexal, Medac, Thermofischer, Lilly, Gilead, Sanofi, BMS, GSK

S. 28 – 30: Medikamentöse Therapie chronischer Herzinsuffizienz.

Von Dr. Benedikt Schrage, Prof. Dr. Dirk Westermann, Prof. Dr. Paulus Kirchhof, PD Dr. Christina Magnussen

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42(36):3599-3726.
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCSD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37(27):2129-2200.
3. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014;370(15):1383-92.
4. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS et al. Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. *N Engl J Med* 2019;381(17):1609-1620.
5. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbuchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. *N Engl J Med* 2020;383(14):1305-1316.
6. Rillig A, Magnussen C, Ozga AK, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns H, Eckardt L, Elvan A, Goette A, Gulizia M, Haegeli L, Heidbuchel H, Kuck KH, Ng A, Szumowski L, van Gelder I, Wegscheider K, Kirchhof P. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. *Circulation* 2021;144(11):845-858.

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2022

Seite 4

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

- Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, Investigators P-C. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J* 2006;27(19):2338-45.
- Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Investigators C, Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet* 2003;362(9386):777-81.
- Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26(3):215-25.
- Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. *Lancet* 2020;396(10244):121-128.
- McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. *Circulation* 2021;143(9):875-877.
- Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM, Group VS. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 2020;382(20):1883-1893.
- osano GMC, Moura B, Metra M, Bohm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Celutkiene J, Chioncel O, Farmakis D, Ferrari R, Filippatos G et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2021;23(6):872-881.
- Spannella F, Giuliotti F, Filipponi A, Sarzani R. Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. *ESC Heart Fail* 2020.
- Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2020;383(15):1436-1446.
- Greene SJ, Khan MS. Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care. *J Am Coll Cardiol* 2021;77(11):1408-1411.
- Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjoström CD, Toto RD, Langkilde AM, Wheeler DC, Committees D-CT, Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2020.
- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H, Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;371(11):993-1004.
- Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParlson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. *Am Heart J* 2018;198:145-151.

Angaben zu möglichen Interessenkonflikten: vorhanden

Die Autoren erklären Vortrags-/Schulungstätigkeit oder Durchführung von klinischen Studien mit folgenden Firmen: Abbott, As-

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2022

Seite 5

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

tra Zeneca, Boston Scientific, Biotronik, Biosense Webster, Boehringer Ingelheim, BSM, Daiichi Sankyo, Farapulse Inc., Medtronic. Die genannten Firmen beziehen sich zusammenfassend auf die Autoren Schlichting, Gunawardene, Willems und Hartmann. Dr. Benjamin Schäffer: Referententätigkeit für die Deutsche Gesellschaft für Kardiologie für den Kurs "Invasive Elektrophysiologie". Benedikt Schrage: Referentenhonorare von AstraZeneca und Abiomed.

Dirk Westermann: Referentenhonorare von Abiomed, AstraZeneca, Bayer, Boehringer-Ingelheim, Novartis, Medtronic.

S. 32 – 33: Der besondere Fall: Schwindelattacken durch Gefäßnervenkonflikt. *Von Prof. Dr. Dr. h.c. Uwe Kehler*

1. Strupp M, Dieterich M, Brandt T. Periphere und zentrale vestibuläre Schwindelformen. Dtsch Arztebl Int 2013; 110(29-30): 505-16; DOI: 10.3238/arztebl.2013.0505.
2. Arning C. Differenzialdiagnose von Schwindelsymptomen. Hamburger Ärzteblatt 2019, Febr, 02: 12-17.
3. Lempert T. Schwindelattacken: Differenzialdiagnose und Therapie. Fortschr Neurol Psychiatr 2005;73: 605–620.
4. Brandt T, Strupp M, Dieterich M. Vestibular paroxysmia: a treatable neurovascular cross-compression syndrome. J Neurol. 2016; 263: 90–96. doi: 10.1007/s00415-015-7973-3.

Angaben zu möglichen Interessenkonflikten: keine

S. 36 – 37: 45 Jahre Karotis-Angioplastie: von der Idee zur Standardtherapie. *Von Prof. Dr. Dr. h. c. Klaus Mathias*

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Circulation 1964;30:654-670.
2. Porstmann W. Ein neuer Korsett-Ballonkatheter zur transluminalen Rekanalisation nach Dotter unter besonderer Berücksichtigung von Obliterationen an den Beckenarterien. Radiol. Diagn. 1973;14:239-244.
3. Grüntzig A, Hopff H. Perkutane Rekanalisation chronischer arterieller Verschlüsse mit einem neuen Dilatationskatheter. Dtsch. Med. Wschr. 1974;99:2502-2505.
4. Zeitler E, Müller R. Ergebnisse mit dert Katheter-Rekanalisation nach Dotter bei arterieller Verschlusskrankheit. Fortschr. Röntgenstr. 1969;111:345-352.
5. Mahler F, Krneta A, Haertel M. Treatment of renovascular hypertension by transluminal renal artery dilatation. Ann. Intern. Med. 1979;90:56-57.
6. Mathias K, Rau W, Kauffmann G. Katheterdilatation einer Arterienstenose nach Nierentransplantation. Dtsch. Med. Wschr. 1979;104:437-438.
7. Mathias K, Staiger J, Thron A, Spillner G, Heiss HW und Konrad-Graf S: Perkutane Katheterangioplastie der Arteria subclavia. Dtsch. Med. Wschr. 1980;106:16-18.
8. Mathias K, Schlosser V, Reinke M. Katheterrekanalisation eines Subklaviaverschlusses. Fortschr. Röntgenstr. 1980;132:346-347.
9. Mathias K. Ein neuartiges Katheter-System zur perkutanen transluminalen Angioplastie von Karotisstenosen. Fortschr. Med. 1977;95:1007-1008.
10. Mathias K, Rohrbach F, Neff W, Ensinger H. Percutaneous transluminal angioplasty (PTA) of carotid artery stenosis. In Zeitler E, Grüntzig A und Schoop W (Ed.): Percutaneous Vascular Rekanalization. Springer Verl. 1978.
11. Mathias K, Mittermayer Ch, Ensinger H, Neff W. Perkutane Katheterdilatation von Karotisstenosen. Fortschr. Röntgenstr. 1980; 133:258-261.